European Medicines Agency approves first-line cabozantinib for advanced kidney cancer
Cabozantinib (Cabometyx) has been granted approval by the Committee for Medicinal [...]
Ipilimumab-nivolumab combination improves overall survival in metastatic kidney cancer
Overall survival data for the ipilimumab-nivolumab combination versus sunitinib from [...]
Cancer immunotherapy
The following publication from Nature reviews various aspects of cancer immunotherapy, [...]
Oncolytic viruses for the treatment of cancer
Oncolytic viruses are modified versions of common viruses, such as [...]
FDA approves monthly dosing schedule for nivolumab
The US Food and Drug Administration (FDA) has approved a [...]
EAU guidelines for the treatment of first-line metastatic kidney cancer to be updated
Further to the results from recent studies, particularly CheckMate-214, the [...]
‘Mini-tumours’ to help predict response to cancer treatments
A new study, published in the journal Science last week, [...]
Treatment of renal cell carcinoma
The following series of interviews with the world's leading kidney [...]
Effect of antibiotics on targeted therapy and immunotherapy for kidney cancer
The following is an interview with Dr Neeraj Agarwal, Associate [...]
Update on papillary kidney cancer
The following is an interview with Dr Ramaprasad Srinivasan, Head of the [...]
